MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
6.5590
-55.4310 (-89.42%)
NASDAQ · Last Trade: Sep 29th, 11:43 AM EDT
Detailed Quote
Previous Close
61.99
Open
6.975
Bid
6.550
Ask
6.560
Day's Range
6.530 - 7.140
52 Week Range
31.42 - 62.75
Volume
46,331,275
Market Cap
-
PE Ratio (TTM)
-2.359
EPS (TTM)
-2.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
839,994
Chart
About MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
MoonLake Immunotherapeutics is a biopharmaceutical company focused on developing novel therapeutics for the treatment of autoimmune and inflammatory diseases. Leveraging its advanced proprietary platform, the company works on innovative approaches to enhance patient outcomes and address unmet medical needs in this therapeutic area. By integrating cutting-edge research and development strategies, MoonLake aims to bring new treatment options to market that can significantly improve the quality of life for individuals affected by chronic diseases. Their commitment to science and patient care drives their mission to transform the landscape of immunotherapy. Read More
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.19% to 46,333.68 while the NASDAQ rose 0.67% to 22,635.76. The S&P 500 also rose, gaining, 0.42% to 6,671.51.
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1 results.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff.
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
